- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Prior Azithromycin therapy associated with reduced susceptibility of gonococcal infections to drug
![Prior Azithromycin therapy associated with reduced susceptibility of gonococcal infections to drug Prior Azithromycin therapy associated with reduced susceptibility of gonococcal infections to drug](https://medicaldialogues.in/h-upload/2020/06/18/750x450_130589-azithromycin.webp)
USA: Subsequent azithromycin reduced susceptibility (AZMRS) gonococcal infections are linked to recent individual-level AZM therapy, says an article published in Clinical Infectious Diseases.
There is contradictory information regarding whether earlier exposure to azithromycin (AZM) reduces a person's sensitivity to it when they have Neisseria gonorrhoeae infection (NG). Emily Rowlinson and colleagues conducted this investigation in order to determine if prior azithromycin exposure has any impact on AZM decreased susceptibility.
The research sample comprised individuals from the Public Health-Seattle & King County Sexual Health Clinic (SHC) with culture-positive NG infection at one anatomic location whose isolates were screened for AZM susceptibility from 2012 to 2019.
Multivariate logistic regression was used to examine the relationship between the time since the last AZM prescription from the SHC in 12 months and subsequent diagnosis with AZMRS NG (minimum inhibitory concentration [MIC] ≥2.0 g/ml), and linear regression was used to assess the relationship between the number of AZM prescriptions in 12 months and AZM MIC level while controlling for demographic, behavioral, and clinical characteristics.
The key findings of this study were:
1. AZMRS NG was substantially related to receipt of AZM from the SHC in the preceding 29 days, but not with receipt of AZM in the prior 30-365 days, in a total of 2,155 unique patients with 2,828 incident NG infections, 156 (6%) of which were caused by AZMRS NG.
2. The log AZM MIC level was not related to the number of AZM prescriptions written within 12 months, however, it was related to the number of prescriptions written within 30 days.
In conclusion, this possibility emphasizes the significance of adhering to existing STD treatment recommendations and employing ceftriaxone monotherapy to treat people with confirmed or suspected gonorrhea infections, or as part of epidemiologic treatment for those who have had sexual contact with someone who has gonorrhea.
Reference:
Rowlinson, E., Soge, O. O., Hughes, J. P., Berzkalns, A., Thibault, C., Kerani, R. P., Khosropour, C. M., Manhart, L. E., Golden, M. R., & Barbee, L. A. (2022). Prior exposure to azithromycin and azithromycin resistance among persons diagnosed with Neisseria gonorrhoeae infection at a Sexual Health Clinic 2012-2019. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, ciac682. https://doi.org/10.1093/cid/ciac682
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751